UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000010582 |
|---|---|
| Receipt number | R000012367 |
| Scientific Title | Multicenter phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320) |
| Date of disclosure of the study information | 2013/04/26 |
| Last modified on | 2020/11/12 10:43:39 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2013/04/24 13:45:41 | ||
| 2 | Update | 2013/10/24 09:59:51 | Email |
|
| 3 | Update | 2014/05/26 10:31:54 | Email1 |
|
| 4 | Update | 2014/07/18 10:40:34 | Email |
|
| 5 | Update | 2015/04/27 15:06:38 | Public title Public title Acronym Acronym |
|
| 6 | Update | 2015/04/27 15:08:08 | Narrative objectives1 Narrative objectives1 |
|
| 7 | Update | 2015/04/27 15:16:39 | Key inclusion criteria Key inclusion criteria Key exclusion criteria Key exclusion criteria |
|
| 8 | Update | 2016/04/25 08:57:53 | Name of primary person or sponsor Organization |
|
| 9 | Update | 2016/04/25 09:27:22 | Control Interventions/Control_1 Interventions/Control_1 |
|
| 10 | Update | 2016/08/16 10:03:52 | Recruitment status Last follow-up date |
|
| 11 | Update | 2018/05/17 09:25:09 | Date analysis concluded |
|
| 12 | Update | 2019/04/24 09:25:58 | Recruitment status Date of IRB Anticipated trial start date |
|
| 13 | Update | 2020/11/12 10:43:39 | URL releasing protocol Publication of results URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
